Zhen Weng1, Jialu Yao2, Raymond H Chan3, Jun He1, Xiangjun Yang2, Yafeng Zhou4, Yang He5. 1. Cyrus Tang Hematology Center and Ministry of Education Engineering Center of Hematological Disease, the First Affiliated Hospital, and the Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. 2. Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou, China. 3. Division of Cardiology, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. 4. Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address: zhouyafeng@medmail.com.cn. 5. Cyrus Tang Hematology Center and Ministry of Education Engineering Center of Hematological Disease, the First Affiliated Hospital, and the Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic address: heyang1963@163.com.
Abstract
OBJECTIVES: The aims of this study included performing a meta-analysis of the predictive value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for adverse events and death in hypertrophic cardiomyopathy (HCM). BACKGROUND: CMR with LGE can identify areas of myocardial fibrosis; however, controversies remain regarding the independent prognostic importance of LGE-CMR in HCM. METHODS: We searched PubMed and Web of Science for studies that investigated the prognostic value of LGE in patients with HCM. Pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated to assess the role of LGE CMR in the risk stratification of HCM. RESULTS: Seven studies were retrieved from 393 citations for the analysis, of which 2 were eliminated because of overlapping data. In total, 2,993 patients (mean age 54.6 years; median follow-up 36.8 months) were included in the analysis. Meta-analysis showed the presence of LGE was associated with an increased risk for sudden cardiac death (SCD) (OR: 3.41; 95% CI:1.97 to 5.94; p < 0.001), all-cause mortality (OR: 1.80, 95% CI: 1.21 to 2.69; p = 0.004), cardiovascular mortality (OR: 2.93, 95% CI: 1.53 to 5.61; p = 0.001), and a trend for heart failure death (OR: 2.21, 95% CI: 0.84 to 5.80; p = 0.107). Extent of LGE was associated with an increased risk of SCD (HR: 1.56/10% LGE; 95% CI: 1.33 to 1.82; p < 0.0001), heart failure death (HR: 1.61/10% LGE; 95% CI: 1.21 to 2.13; p = 0.001), all-cause mortality (HR: 1.29/10% LGE; 95% CI: 1.09 to 1.51; p = 0.002), and cardiovascular mortality (HR: 1.57/10% LGE; 95% CI: 1.30 to 1.89; p < 0.001). After adjusting for baseline characteristics, the extent of LGE remained strongly associated with the risk of SCD (HRadjusted: 1.36/10% LGE; 95% CI: 1.10 to 1.69; p = 0.005). CONCLUSIONS: Quantitative LGE by CMR exhibited a substantial prognostic value in SCD events prediction, independent of baseline characteristics. Assessment of LGE can be used as an effective tool for risk stratifying patients with HCM. Copyright Â
OBJECTIVES: The aims of this study included performing a meta-analysis of the predictive value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for adverse events and death in hypertrophic cardiomyopathy (HCM). BACKGROUND: CMR with LGE can identify areas of myocardial fibrosis; however, controversies remain regarding the independent prognostic importance of LGE-CMR in HCM. METHODS: We searched PubMed and Web of Science for studies that investigated the prognostic value of LGE in patients with HCM. Pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated to assess the role of LGE CMR in the risk stratification of HCM. RESULTS: Seven studies were retrieved from 393 citations for the analysis, of which 2 were eliminated because of overlapping data. In total, 2,993 patients (mean age 54.6 years; median follow-up 36.8 months) were included in the analysis. Meta-analysis showed the presence of LGE was associated with an increased risk for sudden cardiac death (SCD) (OR: 3.41; 95% CI:1.97 to 5.94; p < 0.001), all-cause mortality (OR: 1.80, 95% CI: 1.21 to 2.69; p = 0.004), cardiovascular mortality (OR: 2.93, 95% CI: 1.53 to 5.61; p = 0.001), and a trend for heart failure death (OR: 2.21, 95% CI: 0.84 to 5.80; p = 0.107). Extent of LGE was associated with an increased risk of SCD (HR: 1.56/10% LGE; 95% CI: 1.33 to 1.82; p < 0.0001), heart failure death (HR: 1.61/10% LGE; 95% CI: 1.21 to 2.13; p = 0.001), all-cause mortality (HR: 1.29/10% LGE; 95% CI: 1.09 to 1.51; p = 0.002), and cardiovascular mortality (HR: 1.57/10% LGE; 95% CI: 1.30 to 1.89; p < 0.001). After adjusting for baseline characteristics, the extent of LGE remained strongly associated with the risk of SCD (HRadjusted: 1.36/10% LGE; 95% CI: 1.10 to 1.69; p = 0.005). CONCLUSIONS: Quantitative LGE by CMR exhibited a substantial prognostic value in SCD events prediction, independent of baseline characteristics. Assessment of LGE can be used as an effective tool for risk stratifying patients with HCM. Copyright Â
Authors: Ali Riza Demir; Ömer Celik; Samet Sevinç; Begüm Uygur; Serkan Kahraman; Emre Yilmaz; Mete Cemek; Yilmaz Onal; Mehmet Erturk Journal: Ann Noninvasive Electrocardiol Date: 2019-06-01 Impact factor: 1.468
Authors: Stefan Neubauer; Paul Kolm; Carolyn Y Ho; Raymond Y Kwong; Milind Y Desai; Sarahfaye F Dolman; Evan Appelbaum; Patrice Desvigne-Nickens; John P DiMarco; Matthias G Friedrich; Nancy Geller; Andrew R Harper; Petr Jarolim; Michael Jerosch-Herold; Dong-Yun Kim; Martin S Maron; Jeanette Schulz-Menger; Stefan K Piechnik; Kate Thomson; Cheng Zhang; Hugh Watkins; William S Weintraub; Christopher M Kramer Journal: J Am Coll Cardiol Date: 2019-11-12 Impact factor: 24.094
Authors: Mikko Jalanko; Heikki Väänänen; Mika Tarkiainen; Petri Sipola; Pertti Jääskeläinen; Kirsi Lauerma; Tiina Laitinen; Tomi Laitinen; Mika Laine; Tiina Heliö; Johanna Kuusisto; Matti Viitasalo Journal: Ann Noninvasive Electrocardiol Date: 2018-07-04 Impact factor: 1.468